Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP-938 for acute RSV infection in high-risk non-hospitalized adults
NL-OMON53555Phase 2Not yet recruiting
- Sponsor
- Enanta Pharmaceuticals, Inc.
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing EDP-938 with Placebo (2 arms). Primary endpoint: Time to resolution of RSV lower respiratory tract disease symptoms. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
zelicapavir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on NL-OMON53555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53555.